New drug targets genetic weakness in mesothelioma tumors
NCT ID NCT07602946
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a drug called BMS-986504 in 30 people with relapsed mesothelioma whose tumors have a specific genetic marker (MTAP deficiency). The drug aims to shrink tumors by blocking a protein cancer cells need to grow. Researchers will measure how many patients have their disease controlled at 12 and 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986504 (a targeted drug that blocks a protein called PRMT5, aiming to stop cancer cell growth)
What this could lead to
If it works, this could provide a new targeted treatment option for people with a specific genetic type of relapsed mesothelioma, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects. It is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Leicester Royal Infirmary
Leicester, , LE1 5WW, United Kingdom